© 2021 MJH Life Sciences and Cure Today. All rights reserved.
© 2021 MJH Life Sciences™ and Cure Today. All rights reserved.
Presented by CURE®, a collection of resources that provide information and support for patients with squamous cell carcinoma and the professionals who treat them.
May 7th 2021, 4:00pm
A melanoma survivor pens a poem about his cancer journey, losing his wife to melanoma and how he lives his life after these experiences.
May 7th 2021, 1:00pm
Patients with melanoma treated with Keytruda had improved recurrence-free survival without an effect on their quality of life.
May 3rd 2021, 12:45pm
When caught and treated early, skin cancer is highly curable. When allowed to progress, however, it can cause disfigurement and even death.
April 30th 2021, 4:00pm
Which story – of hope or fear – is the best experience to relate to help another?
April 23rd 2021, 1:00pm
In patients with resected high-risk stage 3 cutaneous melanoma, distant metastasis-free survival at 3.5 years was 65.3% in patients treated with Keytruda compared with 49.4% in those treated with placebo, which was also consistent in patients with PD-L1-positive tumors.
April 22nd 2021, 1:00pm
Keytruda demonstrated clinical benefit for patients with recurrent and metastatic disease, according to an expert.
April 20th 2021, 1:00pm
Active surveillance in sentinel lymph node positive melanoma could delay surgery but may result in the same risk of the cancer coming back.
April 12th 2021, 1:00pm
Chronic immune-related adverse events from anti-PD-1 therapy occur in many patients with advanced melanoma, but shouldn’t deter them from seeking treatment that can provide long-term survival, according to an expert from Vanderbilt University Medical Center.
April 8th 2021, 6:00pm
An expert spoke with CURE® about the FDA’s recent approval of Libtayo to treat patients with locally advanced basal cell carcinoma who previously had only one therapy option for locally advanced disease.
March 19th 2021, 6:00pm
FDA approval of immunotherapies and BRAF/MEK inhibitors may have impacted overall survival, with a change from seven months between 2010 and 2014 to 13 months between 2015 and 2019.
Traveling Amid the COVID-19 Pandemic As A Cancer Survivor
The Definition of ‘Extraordinary’
Oncology Nurses Make ‘the Most Difficult Situation … Much Easier’
Immunotherapy Could “Provide A Whole New Realm” For Patients with Myeloma